Ratings Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Real-time Estimate Tradegate 07:20:54 2024-03-19 am EDT 5-day change 1st Jan Change
25.06 EUR -0.38% Intraday chart for Fresenius SE & Co. KGaA -1.84% -10.83%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-10.83% 15.41B
A-
-11.31% 18.18B
B+
+4.50% 12.8B
B
+1.00% 11.37B
B+
+7.17% 10.64B
B+
+3.08% 8.13B
A-
+13.89% 7.61B
B
+8.89% 6.87B
B-
+6.98% 6.38B
D
+6.17% 4.75B -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock
  2. Equities
  3. Stock Fresenius SE & Co. KGaA - Xetra
  4. Ratings Fresenius SE & Co. KGaA